The growth hormone/insulin-like growth factor system in the management of diabetes and obesity

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

It is well recognised that the growth hormone (GH)/insulin-like growth factor (IGF) system is well recognised to have a role in diabetes and obesity. The IGFs (IGF-I and IGF-II) have structural similarity to proinsulin and the type 1 IGF receptors and insulin receptors are able to form heterodimers that participate in metabolic and mitogenic signalling. Obesity, diabetes and the metabolic syndrome are associated with alterations in the GH/IGF system. Perturbations in this system are also associated with predisposition to diabetes, obesity and the metabolic syndrome and also the risk of vascular and other complications.

Targeting this system holds therapeutic promise. Therefore, having introduced the relevant physiology and pathophysiology, the evidence base in to using GH and IGFs in the management of GH and IGFs therapy will be presented and the advantages and limitations of such approaches will be discussed.
Original languageEnglish
Title of host publicationFrontiers in Clinical Drug Research - Diabetes and Obesity
EditorsAtta ur-Rahman
PublisherBentham eBooks
Pages59-80
Number of pages22
Volume3
ISBN (Electronic)978-1-68108-247-9
ISBN (Print)978-1-68108-248-6
Publication statusPublished - 2016

Publication series

NameFrontiers in Clinical Drug Research – Diabetes and Obesity
PublisherBentham
Volume3
ISSN (Print)2467-9607
ISSN (Electronic)2352-3220

Fingerprint

Somatomedins
Growth Hormone
Obesity
Proinsulin
IGF Type 1 Receptor
Insulin-Like Growth Factor II
Insulin Receptor
Insulin-Like Growth Factor I
Blood Vessels
Therapeutics

Cite this

Lewitt, M. (2016). The growth hormone/insulin-like growth factor system in the management of diabetes and obesity. In A. ur-Rahman (Ed.), Frontiers in Clinical Drug Research - Diabetes and Obesity (Vol. 3, pp. 59-80). (Frontiers in Clinical Drug Research – Diabetes and Obesity; Vol. 3). Bentham eBooks.
Lewitt, Moira. / The growth hormone/insulin-like growth factor system in the management of diabetes and obesity. Frontiers in Clinical Drug Research - Diabetes and Obesity. editor / Atta ur-Rahman. Vol. 3 Bentham eBooks, 2016. pp. 59-80 (Frontiers in Clinical Drug Research – Diabetes and Obesity).
@inbook{d72d04c2e90c4b75bf243ccc06e32c91,
title = "The growth hormone/insulin-like growth factor system in the management of diabetes and obesity",
abstract = "It is well recognised that the growth hormone (GH)/insulin-like growth factor (IGF) system is well recognised to have a role in diabetes and obesity. The IGFs (IGF-I and IGF-II) have structural similarity to proinsulin and the type 1 IGF receptors and insulin receptors are able to form heterodimers that participate in metabolic and mitogenic signalling. Obesity, diabetes and the metabolic syndrome are associated with alterations in the GH/IGF system. Perturbations in this system are also associated with predisposition to diabetes, obesity and the metabolic syndrome and also the risk of vascular and other complications.Targeting this system holds therapeutic promise. Therefore, having introduced the relevant physiology and pathophysiology, the evidence base in to using GH and IGFs in the management of GH and IGFs therapy will be presented and the advantages and limitations of such approaches will be discussed.",
author = "Moira Lewitt",
year = "2016",
language = "English",
isbn = "978-1-68108-248-6",
volume = "3",
series = "Frontiers in Clinical Drug Research – Diabetes and Obesity",
publisher = "Bentham eBooks",
pages = "59--80",
editor = "Atta ur-Rahman",
booktitle = "Frontiers in Clinical Drug Research - Diabetes and Obesity",
address = "Netherlands",

}

Lewitt, M 2016, The growth hormone/insulin-like growth factor system in the management of diabetes and obesity. in A ur-Rahman (ed.), Frontiers in Clinical Drug Research - Diabetes and Obesity. vol. 3, Frontiers in Clinical Drug Research – Diabetes and Obesity, vol. 3, Bentham eBooks, pp. 59-80.

The growth hormone/insulin-like growth factor system in the management of diabetes and obesity. / Lewitt, Moira.

Frontiers in Clinical Drug Research - Diabetes and Obesity. ed. / Atta ur-Rahman. Vol. 3 Bentham eBooks, 2016. p. 59-80 (Frontiers in Clinical Drug Research – Diabetes and Obesity; Vol. 3).

Research output: Chapter in Book/Report/Conference proceedingChapter

TY - CHAP

T1 - The growth hormone/insulin-like growth factor system in the management of diabetes and obesity

AU - Lewitt, Moira

PY - 2016

Y1 - 2016

N2 - It is well recognised that the growth hormone (GH)/insulin-like growth factor (IGF) system is well recognised to have a role in diabetes and obesity. The IGFs (IGF-I and IGF-II) have structural similarity to proinsulin and the type 1 IGF receptors and insulin receptors are able to form heterodimers that participate in metabolic and mitogenic signalling. Obesity, diabetes and the metabolic syndrome are associated with alterations in the GH/IGF system. Perturbations in this system are also associated with predisposition to diabetes, obesity and the metabolic syndrome and also the risk of vascular and other complications.Targeting this system holds therapeutic promise. Therefore, having introduced the relevant physiology and pathophysiology, the evidence base in to using GH and IGFs in the management of GH and IGFs therapy will be presented and the advantages and limitations of such approaches will be discussed.

AB - It is well recognised that the growth hormone (GH)/insulin-like growth factor (IGF) system is well recognised to have a role in diabetes and obesity. The IGFs (IGF-I and IGF-II) have structural similarity to proinsulin and the type 1 IGF receptors and insulin receptors are able to form heterodimers that participate in metabolic and mitogenic signalling. Obesity, diabetes and the metabolic syndrome are associated with alterations in the GH/IGF system. Perturbations in this system are also associated with predisposition to diabetes, obesity and the metabolic syndrome and also the risk of vascular and other complications.Targeting this system holds therapeutic promise. Therefore, having introduced the relevant physiology and pathophysiology, the evidence base in to using GH and IGFs in the management of GH and IGFs therapy will be presented and the advantages and limitations of such approaches will be discussed.

M3 - Chapter

SN - 978-1-68108-248-6

VL - 3

T3 - Frontiers in Clinical Drug Research – Diabetes and Obesity

SP - 59

EP - 80

BT - Frontiers in Clinical Drug Research - Diabetes and Obesity

A2 - ur-Rahman, Atta

PB - Bentham eBooks

ER -

Lewitt M. The growth hormone/insulin-like growth factor system in the management of diabetes and obesity. In ur-Rahman A, editor, Frontiers in Clinical Drug Research - Diabetes and Obesity. Vol. 3. Bentham eBooks. 2016. p. 59-80. (Frontiers in Clinical Drug Research – Diabetes and Obesity).